1. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms
   Lijun Yang et al, 2017, Journal of Chemotherapy CrossRef
2. Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine
   Mahmoud Younis et al, 2024, Pharmacogenomics and Personalized Medicine CrossRef
3. Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice
   Shibo Qi et al, 2014, International Journal of Molecular Sciences CrossRef
4. High BMI1 Expression with Low CD8+ and CD4+ T Cell Activity Could Promote Breast Cancer Cell Survival: A Machine Learning Approach
   Yumin Chung et al, 2021, Journal of Personalized Medicine CrossRef
5. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy
   James Griffith et al, 2017, Oncology Reports CrossRef
6. Role of liver stem cells in hepatocarcinogenesis
   Lei-Bo Xu, 2014, World Journal of Stem Cells CrossRef
7. Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia
   Avinash Chandra Kushwaha et al, 2020, ACS Applied Materials & Interfaces CrossRef
8. Emerging Regulatory Mechanisms Involved in Liver Cancer Stem Cell Properties in Hepatocellular Carcinoma
   Duoduo Lv et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
9. Inducing Differentiation of Premalignant Hepatic Cells as a Novel Therapeutic Strategy in Hepatocarcinoma
   Benita Wolf et al, 2016, Cancer Research CrossRef
10. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1
    Wen-rui Wu et al, 2016, Oncotarget CrossRef
11. Biocompatible co-loading vehicles for delivering both nanoplatin cores and siRNA to treat hepatocellular carcinoma
    Minsi Li et al, 2019, International Journal of Pharmaceutics CrossRef
12. Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical Applications
    Mahmoud A. Younis et al, 2020, Advanced Therapeutics CrossRef
13. Dysregulation of Bmi1 promotes malignant transformation of hepatic progenitor cells
    R Zhang et al, 2016, Oncogenesis CrossRef
14. Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules
    Tan Yang et al, 2018, Nanomedicine: Nanotechnology, Biology and Medicine CrossRef
15. ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma
    Kaori Tanaka et al, 2015, Oncotarget CrossRef
16. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma
    Ru Wang et al, 2022, Technology in Cancer Research & Treatment CrossRef
17. Prognosis of hepatocellular carcinoma patients with bile duct tumor thrombus after hepatic resection or liver transplantation in Asian populations: A meta-analysis
    Chenglin Wang et al, 2017, PLOS ONE CrossRef
18. The Role of Stem Cells in the Hepatobiliary System and in Cancer Development: a Surgeon’s Perspective
    Naoto Koike, 2018, Stem Cells and Cancer in Hepatology CrossRef
19. EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c
    Leibo Xu et al, 2020, Oncogenesis CrossRef